Related Experiment Video
Updated: Sep 26, 2026

Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
[Serological tests for detection of fungal infection connected with prolonged antibiotic treatment after valve
Unlabelled:
In recent years substantial progress has been seen in the development of approaches and methods for serological diagnosis of the mycosis. The aim of our study was to assess the clinical usefulness of serological tests for fungal infection in pts who underwent prolonged antibiotic therapy after valve replacement.
Material And Methods:
The group consisted of 27 pts after valve replacement with prolonged antibiotic therapy (6-12 weeks) due to infective endocarditis (22 pts) or sternal infection (5 pts). The samples of blood were taken 10 days after antibiotics were started and next every 10 days. Serological techniques for the diagnosis of Candidiasis consisted of antibody detection to: the cell wall polysaccharide antigen (test A), cytoplasmic protein antigen (test B) and the germ tube antigens (test C).
Results:
Patients were divided in 3 groups due to the kinetics of the antibody responses to the Candida antigen: 1. pts with normal level of antibody during antibiotic treatment--they didn't required antifungal therapy, 2. pts with increasing level of antibody needed antifungal treatment, 3. pts with increasing kinetics of antibody responses during antibiotic and antifungal treatment needed the change of antifungal therapy, 4. Control group (pts before cardiac surgery without any sign of fungal infection). Antibody to the cytoplasmic antigen was detected infrequently. The presence of antibody to the cytoplasmic antigen was correlated with the patient clinical outcome and prognosis and necessity for change of antifungal therapy. One pt died after valve replacement due to valve dysfunction because of fungal endocarditis.
Conclusions:
Serological tests for Candidiasis can be a useful marker of fungal infection, prognosis and treatment in pts required prolonged antibiotic therapy after valve replacement.
Insights
Serological tests for fungal infections aid in diagnosing and managing patients after valve replacement who receive prolonged antibiotic therapy. Monitoring antibody levels helps determine the need for antifungal treatment and guides therapy adjustments.
Area of Science:
- Medical Mycology
- Clinical Diagnostics
- Infectious Diseases
Background:
- Fungal infections pose a significant risk in patients undergoing valve replacement, especially those requiring prolonged antibiotic therapy.
- Accurate and timely diagnosis is crucial for effective management and improved patient outcomes.
Observation:
- The study included 27 patients who underwent valve replacement and received 6-12 weeks of antibiotic therapy for infective endocarditis or sternal infections.
- Blood samples were collected serially to detect antibodies against Candida antigens (cell wall polysaccharide, cytoplasmic protein, germ tube).
Findings:
- Patients were categorized based on antibody response kinetics: normal levels (no antifungal therapy needed), increasing levels (antifungal treatment required), and increasing kinetics during both antibiotic and antifungal treatment (therapy change indicated).
- Antibodies to cytoplasmic antigen were infrequently detected but correlated with clinical outcomes, prognosis, and the need for antifungal therapy adjustment.
- One patient died due to valve dysfunction caused by fungal endocarditis.
Implications:
- Serological tests for Candidiasis serve as valuable markers for diagnosing fungal infections in patients receiving prolonged antibiotic therapy post-valve replacement.
- These tests aid in predicting prognosis and guiding treatment decisions, potentially improving patient outcomes.
- The findings support the integration of serological diagnostics into the management of post-cardiac surgery infections.
Related Concept Videos
Urine Studies II: Urine Culture and Sensitivity Test
Automated Microbial Diagnostics
Mitral Stenosis III: Medical Management
